Roche moves obesity asset CT-388 into Phase III - European Biotechnology Magazine

Retrieved on: 2025-09-22 19:54:11

Tags for this article:

Click the tags to see associated articles and topics

Roche moves obesity asset CT-388 into Phase III - European Biotechnology Magazine. View article details on hiswai:

Excerpt

With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by 2030, Roche Pharma CEO Teresa Graham said at Roche's ...

Article found on: european-biotechnology.com